



Cite this: *RSC Adv.*, 2020, **10**, 2915

Synthesis of new piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of *Candida albicans* multidrug transporters by a Buchwald–Hartwig cross-coupling reaction†

Jean Guillon,^{‡,a} Shweta Nim,^{‡,b} Stéphane Moreau,^a Luisa Ronga,^a Solène Savrimoutou,^a Elisabeth Thivet,^a Mathieu Marchivie,^c Attilio Di Pietro,^d Rajendra Prasad^e and Marc Le Borgne  ^{*,f}

Two series of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives were prepared *via* a Buchwald–Hartwig cross-coupling reaction and then evaluated for their ability to inhibit the drug efflux activity of CaCdr1p and CaMdr1p transporters of *Candida albicans* overexpressed in a *Saccharomyces cerevisiae* strain. In the initial screening of twenty-nine piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives, twenty-three compounds behaved as dual inhibitors of CaCdr1p and CaMdr1p. Only four compounds showed exclusive inhibition of CaCdr1p or CaMdr1p. Further biological investigations were developed and for example, their antifungal potential was evaluated by measuring the growth of control yeast cells (AD1-8u⁺) and efflux pump-overexpressing cells (AD-CDR1 and AD-MDR1) after exposition to variable concentrations of the tested compounds. The MIC₈₀ values of nineteen compounds ranging from 100 to 901 μM for AD-CDR1 demonstrated that relative resistance index (RI) values were between 8 and 274. In comparison, only seven compounds had RI values superior to 4 in cells overexpressing Mdr1p. These results indicated substrate behavior for nineteen compounds for CaCdr1p and seven compounds for CaMdr1p, as these compounds were transported *via* MDR transporter overexpressing cells and not by the AD1-8u⁺ cells. Finally, in a combination assay with fluconazole, two compounds (**1d** and **1f**) have shown a synergistic effect (fractional inhibitory concentration index (FICI) values ≤ 0.5) at micromolar concentrations in the AD-MDR1 yeast strain overexpressing CaMdr1p-protein, indicating an excellent potency toward chemosensitization.

Received 10th November 2019
 Accepted 30th December 2019

DOI: 10.1039/c9ra09348f
rsc.li/rsc-advances

Introduction

Transplantation surgery, cancer chemotherapy, and HIV infections have led to a worldwide rise of the immunocompromised population, and hence also of bacterial and fungal opportunistic infections.¹ The fungal genera most often associated with

invasive fungal infections include *Candida*, *Aspergillus*, and *Cryptococcus*,² with opportunistic strains of *Candida albicans* accounting for approximately 50–60% causes of candidiasis, particularly in immunocompromised patients. The treatment of these *Candida* infections relies heavily on azole antifungal agents,³ for which widespread and prolonged use has led to the rapid emergence of multidrug resistant (MDR) isolates of *C. albicans* as well as of non-*albicans* species.⁴ Various mechanisms potentially contributing to the development of MDR have been identified, and the induction of genes encoding drug-efflux pumps, like the primary ATP binding cassette (ABC) transporter genes CaCDR1 and CaCDR2 and the secondary major-facilitator superfamily (MFS) transporter gene CaMDR1, has been shown to play a prominent role in the development of resistance to antifungal drugs.^{5–7} Overexpression of these pump proteins may lead to an increased efflux of drug substrates in MDR clinical isolates.^{4,8,9}

The potent modulators of multidrug transporter CaCdr1p such as the immunosuppressants cyclosporin, FK520 and FK506, the natural polyphenol curcumin, the quorum-sensing

^aUniv. Bordeaux, INSERM U1212 – UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, F-33076 Bordeaux Cedex, France

^bSchool of Life Sciences, Jawaharlal Nehru University, 110067 New Delhi, India

^cCNRS, Univ. Bordeaux, Bordeaux INP, ICMCB, UMR 5026, F-33608 Pessac Cedex, France

^dDRMP Group, IBCP, UMR 5086 (MMSB), CNRS/Lyon I University, 69367 Lyon, France

^eAmity Institute of Integrative Sciences and Health, Amity University, Education Valley, Gurgaon 122413, India

^fUniversité de Lyon, Université Claude Bernard Lyon 1, Faculté de Pharmacie – ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453 – INSERM US7, Lyon, France. E-mail: marc.le-borgne@univ-lyon1.fr

† Electronic supplementary information (ESI) available. CCDC 891808 and 891809. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9ra09348f

‡ These authors contributed equally to this work.

molecule farnesol, the antabuse drug disulfiram, the antibiotic milbemycin, some synthetic-D-octapeptides, the anti-inflammatory drug ibuprofen and the antibacterial unnamicins have been displayed to prevent drug extrusion and restore fungicidal synergism with the azoles and other drugs.^{10–14} Unlike CaCdr1p, there is only a handful number of chemosensitizers in case of CaMdr1p such as verapamil and enniantin B.^{15,16} Recently, a further screening from a library of synthetic aromatic compounds sharing a cyclobutene-dione moiety was investigated for the discovery of new inhibitors of MFS and ABC transporters of *C. albicans*. A few specific inhibitors of MFS transporter CaMdr1p were then identified.¹⁷ Therefore, the search for novel inhibitors able to block the drug extrusion mediated by these efflux proteins represents an attractive approach to reverse MDR.

The pyrrolo[1,2-*a*]quinoxaline heterocyclic framework constitutes the basis of an important class of compounds possessing interesting biological activities. These compounds have been reported as key intermediates for the assembly of several heterocycles including antipsychotic agent,¹⁸ anti-HIV agent,¹⁹ adenosine A₃ receptor modulator,²⁰ antiparasitic agents,^{21–25} and antitumor agents.^{26–31} We also previously demonstrated that the pyrrolo[1,2-*a*]quinoxaline heterocyclic scaffold could lead to the preparation of bacterial multidrug resistance pump inhibitors.^{32,33}

In this context and as part of a programme on the development of new efflux pump inhibitors (EPIs), we decided to broaden the structural diversity and used the pyrrolo[1,2-*a*]quinoxaline moiety as a template for the design of new derivatives **1** and **2** in which a piperazine is incorporated in position 1, 4 or 9 of the heterocyclic core in analogy with the EPI pyrimidine and quinoline derivatives **I–III**, quinine and MS-209 used in the various multidrug resistance therapies (Fig. 1).^{34–38}

Results and discussion

Chemistry

The reported piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives **1a–i** were synthesized in five steps from 2-nitroaniline (Scheme 1). Preparation of 1-(2-nitrophenyl)pyrrole **2** was performed according to the Clauson–Kaas reaction run under micro-wave irradiation starting from 2-nitroaniline and 2,5-dimethoxytetrahydrofuran in acetic acid. This pathway partially involved synthetic methodologies already described by our group.^{21–24,28} The resulting 1-(2-nitrophenyl)pyrrole intermediate **2** was subsequently reduced into the attempted 1-(2-aminophenyl)pyrrole **3** using a sodium borohydride-copper(II) sulfate treatment in ethanol at room temperature. This NaBH₄–CuSO₄ system was found to be quite powerful in reducing our aromatic nitro group with excellent yield (85%). The reaction of **3** with triphosgene in toluene gave the lactam **4**, which was subsequently chlorodehydroxylated with phosphorous oxychloride, leading to the 4-chloropyrrolo[1,2-*a*]quinoxaline **5a**. The 4-phenylpyrrolo[1,2-*a*]quinoxaline **6** was easily prepared by a direct Suzuki–Miyaura cross-coupling reaction of 4-chloropyrroloquinoxalines **5a** with potassium phenyltrifluoroborate performed in the presence of PdCl₂(dppf)·CH₂Cl₂ as a catalyst,

cesium carbonate as the base, and THF–H₂O as the solvent system.²³ Reaction of **6** and one equivalent of *N*-bromosuccinimide (NBS) afforded the 1-bromo-4-phenylpyrrolo[1,2-*a*]quinoxaline **7** as the sole reaction product.²⁸ The Buchwald–Hartwig Pd-catalyzed amination of the 1-bromo-4-phenylpyrrolo[1,2-*a*]quinoxaline **7** using Pd₂(dba)₃ as catalyst with BINAP as the ligand was then investigated. Under these conditions, various substituted piperazines were successfully coupled with **7** to give the desired piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives **1a–i** by using *t*-BuONa as a base and toluene as the solvent at 100 °C.^{39–41}

The 3D structural determinations of **1a** and **1h** were established by X-ray crystallography (Fig. 2 and 3), and confirmed the structures in the solid state as anticipated on the basis of NMR data.

By using the same cross-coupling catalyzed methodology, the Pd-catalyzed coupling of substituted piperazines with the 4-chloropyrrolo[1,2-*a*]quinoxalines **5a–e**³⁰ led to the new 4-(4-substituted-piperazinyl)-4-phenylpyrrolo[1,2-*a*]quinoxaline **1j–w** (Scheme 2). These compounds **1a–w** were then converted into their hydrochloride or oxalate salts (Table 1).

The series of piperazinylalcohol pyrrolo[1,2-*a*]quinoxaline derivatives **2a–f** was synthesized as previously described by the authors starting from **5a** or **8** (Schemes 3 and 4).⁴²

Biological assays

Piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives were evaluated for their ability to inhibit the drug-efflux activity of CaCdr1p and CaMdr1p transporters of *C. albicans* overexpressed in a *Saccharomyces cerevisiae* strain. The transport assay was performed by monitoring Nile Red (NR) efflux in cells overexpressing the referred efflux pumps. In this assay, compounds were compared to wild-type control cells, and when the Nile Red efflux was lower than 60%, the compound was indeed considered to have inhibitory activity (Fig. 4). The efflux study performed on twenty-nine compounds revealed the total of twenty-three compounds (**1a**, **1b**, **1e**, **1g**, **1h**, **1i**, **1j**, **1k**, **1l**, **1m**, **1n**, **1o**, **1p**, **1s**, **1t**, **1u**, **1v**, **1w**, **2a**, **2c**, **2d**, **2e**, **2f**) that behaved as dual inhibitors of CaCdr1p and CaMdr1p. Compounds **2c** > **2d** > **1j** = **1l** = **1o** = **1v** revealed the strongest inhibitory activity of Cdr1p efflux pump, ranging from 77 to 82%. Regarding *S. cerevisiae* cells overexpressing Mdr1p, the most active compounds were **2f** > **2c** > **1a** = **1b** = **1j** = **1k** = **1n** = **1s** = **1t** = **2a** = **2d** > **1l** > **1o** ranging from 78 to 84% efflux inhibition. This initial screening identified compounds **1u**, **1w** and **2e** as dual inhibitors with intermediate potency. Compounds **1e**, **1g**, **1h**, **1i**, **1m**, **1p** finally revealed a weak inhibitory activity in both cell lines overexpressing the two types of efflux pumps. Compound **1c** and **1f** showed exclusive but weak inhibition of CaCdr1p, whereas compounds **1d** and **1q** demonstrated their exclusive impact on CaMdr1p with efflux inhibition ranged from 29 to 50%. Compounds **1r** and **2b** are not active on both efflux pumps.

The antifungal potential of all piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives was also evaluated by measuring the growth of control yeast cells (AD1-8u[–]) and efflux pump-overexpressing cells (AD-CDR1 and AD-MDR1) when exposed





Fig. 1 Structures of previously described EPIs I–III, quinine and MS-209, and new synthesized substituted pyrrolo[1,2-a]quinoxaline derivatives 1–2.

to variable concentrations of the tested compounds for 48 h. The yeast growth in the absence of inhibitor was considered as 100%. The results were expressed as MIC_{80} , the concentration

needed to decrease 80% of cells growth (ESI Table S1†). In case of the control yeast cells (AD1-8u[−]), compounds did not reveal any significant antifungal activity, as demonstrated by their





Scheme 1 Synthesis of 1-(4-substituted-piperazinyl)-4-phenylpyrrolo[1,2-a]quinoxalines **1a-i**; reagents and conditions: (i) 2,5-diMeOTHF, AcOH, Δ ; (ii) $\text{CuSO}_4/\text{NaBH}_4$, EtOH, RT; (iii) $(\text{Cl}_3\text{CO})_2\text{CO}$, toluene, Δ ; (iv) POCl_3 , Δ ; (v) $(\text{OHC-C}_6\text{H}_4)-\text{BF}_3\text{K}$, $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$, Cs_2CO_3 , $\text{THF-H}_2\text{O}$, Δ ; (vi) NBS , CH_2Cl_2 , RT; (vii) R-piperazine , $\text{Pd}_2(\text{dba})_3$, BINAP, $t\text{-BuONa}$, toluene, $100\text{ }^\circ\text{C}$.

relative resistance index (RI) values close to 1. However the MIC_{80} values of nineteen selected compounds (Table 2) ranging from 100 to 901 μM for AD-CDR1 demonstrated that RI values were comprised between 8 and 274. In comparison, only seven

compounds (**1c**, **1e**, **1g**, **1j**, **1k**, **1m**, **1o**) had RI values superior to 4 in cells overexpressing Mdr1p. These results indicate the substrate behavior for both 19 compounds for CaCdr1p and seven compounds for CaMdr1p, as these compounds are






Fig. 2 The ORTEP drawing of pyrrolo[1,2-a]quinoxaline **1a** with thermal ellipsoids at 30% level.

transported *via* MDR transporter overexpressing cells and not by the AD1-8u⁻ cells. Interestingly, all the nineteen compounds were observed to inhibit the Nile Red transport from the AD-CDR1 cells and simultaneously behaved as substrate of CaCdr1p (Table 2). Then it could be suggested that the Nile Red and these compounds seem to share the same drug binding pocket of CDR1, undergoing the kinetics of competitive inhibition. By contrast, in the case of AD-MDR1 cells, the route of efflux transport for Nile Red and these compounds did not overlap as only seven compounds showed substrate behavior. Here the results suggest the presence of an allosteric drug binding pocket for MDR1 and thus following the path of non-competitive kinetics.

The ability of the compounds to sensitize yeast growth to the antifungal agent fluconazole was evaluated by the checkerboard method.⁴³ In this assay, the control (AD1-8u⁻) cells and the CaCdr1p- and CaMdr1p-overexpressing cells were grown in the presence of either fluconazole alone or a combination therapy (efflux pump inhibitor plus fluconazole). The results, expressed

as the fractional inhibitory concentration index (FICI), are summarized in ESI Table S2.† FICI values ≤ 0.5 indicate synergistic interaction between the inhibitor and the substrate.⁴⁴ It was observed that the two piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives **1d** and **1f** with FIC = 0.0076 and 0.25, respectively, displayed strong synergistic effects (FICI = 0.15 and 0.4, respectively) when both are combined with fluconazole (FIC = 0.15) in the AD-MDR1 yeast strain overexpressing the MFS CaMdr1p, decreasing 129-fold the MIC₈₀ of the antifungal agent. High FICI values (≥ 1) were found for the remaining compounds (ESI Table S2†). Similarly, high FICI values were also found in the AD-CDR1.

The effect of the compounds **1d** and **1f** was examined by confocal imaging of GFP-tagged Cdr1p and Mdr1p, and revealed the non-effect of these compounds on the intactness of the overexpressing strains AD-CDR1 and AD-MDR1 (Fig. 5).

Finally, compounds **1d** and **1f** were further evaluated for their ability to chemosensitize the azole-resistant clinical isolate (F5) of *C. albicans* together with the azole-susceptible strain






Fig. 3 The ORTEP drawing of pyrrolo[1,2-a]quinoxaline **1h** (molecules A and B) with thermal ellipsoids at 30% level.

(F2).^{45,46} As can be observed in Table 3, when combined with fluconazole, compounds **1d** and **1f** (FICI = 0.6 and 0.78, respectively) were able to reduce the effective concentration of fluconazole.

About the structure-activity relationships on both series of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives, the three best dual inhibitors belonging to the series 2 (**2c**, **2d**, **2f**) has a common structural feature, namely the presence of a spacer (oxy-propan-2-ol or amino-propan-2-ol) between the tricyclic scaffold and the piperazinyl moiety. On the other hand, exclusive inhibitors of CaCdr1p (**1c**, **1f**) or CaMdr1p (**1d**, **1q**) have the piperazinyl moiety directly linked to the pyrroloquinoxaline. Four of these compounds (**2c**, **2f**, **1d** and **2d**) have a benzhydryl substituent or related on the piperazine ring. Further pharmacomodulation works will be carried out to extend and deepen our knowledge.


Conclusions

The chemical approach by Buchwald–Hartwig Pd-catalyzed amination of the 1-bromo-4-phenylpyrrolo[1,2-a]quinoxaline 7 or the 4-chloropyrrolo[1,2-a]quinoxalines **5a–e** was successfully used to access to new piperazinyl-pyrrolo[1,2-a]quinoxaline

derivatives **1a–w**. In parallel, six other derivatives containing as well a quinoxaline moiety (compounds **2a–f**, previously synthesized⁴²) were added to this study. Then twenty-nine compounds have been selected on their potential to inhibit fungal multidrug resistance pumps as pyrrolo[1,2-a]quinoxaline template was already used and efficient for the inhibition of bacterial efflux pumps.^{32,33}

Currently, we broadened our horizon to look into the role of these compounds to inhibit the CaCdr1p and CaMdr1p transporters in pathogenic yeast *C. albicans*. Our study based on the biological assays corroborated with the piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives to be the putative and promising modulators of efflux pumps in the pathogenic yeast *C. albicans*. The results of this work have demonstrated that most of the compounds could inhibit the efflux of Nile Red mediated by both the ABC transporter CaCdr1p and the MFS pump CaMdr1p. Some compounds were able to inhibit specifically the efflux of Nile Red without being themselves substrates of the efflux-pump proteins CaMdr1p and CaCdr1p. This assumption was corroborated by the relative resistance index values close to 1 obtained from the cytotoxicity assays, showing that the presence of efflux-pump proteins did not affect the growth and the viability of yeast cells.





Scheme 2 Synthesis of 4-(4-substituted-piperazinyl)-4-phenylpyrrolo[1,2-a]quinoxalines **1j-w**; reagents and conditions: (i) *R*-piperazine, $Pd_2(dba)_3$, BINAP, t -BuONa, toluene, $100\text{ }^\circ\text{C}$.

In *S. cerevisiae* cells expressing CaCdr1p and CaMdr1p, the greater inhibitory effect on Nile Red efflux was obtained with compounds **2c-f** ($5 < MIC_{80} \text{ } (\mu\text{M}) < 14$) on CaMdr1p. For compounds **2c-e**, the best three compounds ($MIC_{80} = 5-6 \text{ } \mu\text{M}$), the main structural feature is the presence of a bulky group *R* (*e.g.* compound **2c** with a diphenylmethyl moiety).

In the combination assay with fluconazole, the two compounds **1d** and **1f** have shown a synergistic effect (FICI values ≤ 0.5) at micromolar concentrations in the AD-MDR1 yeast strain overexpressing CaMdr1p-protein, indicating an excellent potency toward chemosensitization. Interestingly, compound **1d** showed exclusive and maximum Nile Red efflux inhibition on AD-MDR1 strain and showed excellent chemosensitization in the presence of fluconazole, whereas this was

not observed with compound **1f**. In this context, it is important to mention that each drug/compound may interact differently with different amino acid residues within the binding pocket of CaMdr1p, which could explain the different behavior of Nile Red and fluconazole with these compounds. As no synergy has been found in the clinical isolate F5 overexpressing CaMdr1p, a significant decreasing of the effective concentration of the antifungal agent was also observed, corroborating the results obtained in the AD-MDR1 strain. It is also interesting to note that compound **1d** is the unique active compound bearing a benzhydryl moiety in the sub-series **1**.

Finally, this study has shown that piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives are able to reverse antifungal resistance, mediated by efflux pumps belonging to both ABC and MFS



Table 1 Physical properties of the final amines **1a–w**

| Compound | ^{a,b,c} Salt | ^d mp (°C) | ^e Yield (%) |
|-----------|--|----------------------|------------------------|
| 1a | 3HCl | 114 | 71 |
| 1b | 3HCl | 88 | 68 |
| 1c | (COOH) ₂ , H ₂ O | 172 | 58 |
| 1d | (COOH) ₂ , H ₂ O | 109 | 61 |
| 1e | (COOH) ₂ , H ₂ O | 175 | 52 |
| 1f | (COOH) ₂ , H ₂ O | 156 | 59 |
| 1g | (COOH) ₂ , H ₂ O | 241 | 53 |
| 1h | (COOH) ₂ , H ₂ O | 238 | 64 |
| 1i | (COOH) ₂ , H ₂ O | 93 | 59 |
| 1j | 2(COOH) ₂ | 203 | 66 |
| 1k | 2(COOH) ₂ | 144 | 61 |
| 1l | 2(COOH) ₂ | 189 | 72 |
| 1m | 2(COOH) ₂ | 236 | 74 |
| 1n | 2(COOH) ₂ | 228 | 67 |
| 1n | 2(COOH) ₂ | 215 | 82 |
| 1o | 2(COOH) ₂ | 194 | 59 |
| 1p | 2(COOH) ₂ | 190 | 63 |
| 1q | 2(COOH) ₂ | 189 | 67 |
| 1r | 2(COOH) ₂ | 212 | 64 |
| 1s | 2(COOH) ₂ | 225 | 71 |
| 1t | 2(COOH) ₂ | 190 | 60 |
| 1u | 2(COOH) ₂ | 180 | 75 |
| 1v | 2(COOH) ₂ | 251 | 62 |
| 1w | 2(COOH) ₂ | 253 | 60 |


^a The amines **1a**, **b** were dissolved in 20 mL of anhydrous diethyl ether, and treated with HCl gas. After crystallization, the ammonium chlorides were collected by filtration and were washed with Et₂O, then dried under reduced pressure. ^b The amines **1c–w** were dissolved in 30 mL of 2-propanol, heated to boiling, and treated with oxalic acid (4 or 5 equiv., based on the amount of the starting material). The oxalate salts crystallized upon cooling were collected by filtration, and were washed with 2-propanol and Et₂O. ^c The stoichiometry and composition of the salts were determined by elemental analyses (within \pm 0.4% of the theoretical values). ^d Crystallization solvent: 2-PrOH–H₂O. ^e The yields only included the conversions into the ammonium chlorides or oxalates.


superfamilies of transporters of the pathogenic yeast *C. albicans*. Therefore, at non-inhibitory concentrations, these compounds stand as wise candidates chosen to be potential modulators in MDR reversal. For example, compound **1d** could offer a new treatment strategy known as combo-therapy in the use of new azole antifungals recently designed.^{47,48} Nevertheless further chemical modifications will be carried out to synthetize a second generation of piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives designed specifically as EPIs of the pathogenic yeast *C. albicans*. Once again, compound **1d** will be investigated for assessing the structural importance of its benzhydryl moiety (e.g. nature and position of additional substituents). By similarity, a pharmacomodulation study around compound **2c** will be also managed, using rational drug design tools such as 3D structural characteristics of efflux pumps⁴⁹ and recent chemical features⁵⁰ to design new piperazinyl-pyrrolo[1,2-*a*]quinoxaline derivatives as specific EPIs of *C. albicans*.

Experimental section

Chemistry

General information. Commercially reagents were used as received without additional purification. Melting points were determined with an SM-LUX-POL Leitz hot-stage microscope and are uncorrected. NMR spectra were recorded with tetramethylsilane as an internal standard using a Bruker Avance 300 spectrometer. Splitting patterns have been designated as follows: s = singlet; bs = broad singlet; d = doublet; t = triplet; q = quartet; dd = double doublet; ddd = double double doublet; dt = double triplet; m = multiplet. For all compounds **1a–w**, all NMR spectra are available in the ESI (Fig. S1–S45†). Analytical TLC were carried out on 0.25 precoated silica gel plates (POLYGRAM SIL G/UV254) and visualization of compounds after UV light irradiation. Silica gel 60 (70–230

Scheme 3 Synthesis of piperazinylalcohol-pyrrolo[1,2-*a*]quinoxalines **2a–e**; reagents and conditions: (i) K₂CO₃, DMF, 120 °C.



Scheme 4 Synthesis of piperazinylalcohol-pyrrolo[1,2-a]quinoxaline 2f; reagents and conditions: (i) $(C_6H_5)_2CH$ -piperazine, isopropanol, Δ .

mesh) was used for column chromatography. Elemental analyses were found within $\pm 0.4\%$ of the theoretical values.

General procedure: synthesis of 1-piperazinyl-4-phenyl-pyrrolo[1,2-a]quinoxalines 1a-w. To a solution of 2.5 mmol of 1-bromo-4-phenylpyrrolo[1,2-a]quinoxaline 7 or 4-chloropyrrolo[1,2-a]quinoxaline 5a-e in 18 mL of anhydrous toluene were added 3 mmol (1.2 equiv.) of substituted piperazine, 0.333 g (3.5 mmol, 1.4 equiv.) of *t*-BuONa, 0.046 g (0.05 mmol, 0.02 equiv.) of tris(dibenzylideneacetone)dipalladium (0) $[Pd_2(dbu)_3]$ and 0.062 g (0.1 mmol, 0.04 equiv.) of 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene [(\pm)-BINAP]. The reaction mixture was then heated at 100 $^{\circ}C$ during 15 h. After cooling, the mixture was diluted with methylene chloride. The reaction mixture was then filtered on Celite and then diluted with water. The organic layer was separated and the aqueous layer was extracted with methylene chloride (20 mL). The organic layers were collected, dried over magnesium sulfate, filtered and evaporated to dryness. Column chromatography of the residue on silica gel using ethyl acetate-methanol (8/2) as eluent gave the final product 1.

1-(4-Phenylpiperazinyl)-4-phenylpyrrolo[1,2-a]quinoxaline (1a). Yellow crystals (48%) mp 203 $^{\circ}C$. 1H NMR ($CDCl_3$) δ 9.21 (dd, 1H, J = 8.10 and 2.80 Hz, H-9), 8.02 (dd, 1H, J = 8.10 and 2.80 Hz, H-6), 7.96–7.93 (m, 2H, H-2' and H-6'), 7.57–7.52 (m, 3H, H-3', H-4' and H-5'), 7.47–7.43 (m, 2H, H-7 and H-8), 7.35 (t, 2H, J = 7.70 Hz, H-3'' and H-5''), 7.07 (d, 2H, J = 7.70 Hz, H-2'' and H-6''), 6.96 (t, 1H, J = 7.70 Hz, H-4''), 6.92 (d, 1H, J = 4.30 Hz, H-2), 6.59 (d, 1H, J = 4.30 Hz, H-3), 3.78–3.74 (m, 2H, CH_2 -pip), 3.51–3.47 (m, 2H, CH_2 -pip), 3.31–3.26 (m, 2H, CH_2 -

pip), 3.18–3.09 (m, 2H, CH_2 -pip). ^{13}C NMR ($CDCl_3$) δ 156.1 (C-4), 152.6 (C-1''), 145.1 (C-3a), 139.4 (C-5a), 138.4 (C-1''), 131.2 (C-7), 130.7 (C-8, C-3'' and C-5''), 130.2 (C-3' and C-5''), 130.1 (C-9a), 130.0 (C-2' and C-6'), 127.7 (C-9), 126.5 (C-6), 123.5 (C-1), 121.8 (C-4''), 117.9 (C-4''), 117.8 (C-2'' and C-6''), 109.9 (C-2), 104.7 (C-3), 53.8 (CH_2 -pip), 50.6 (CH_2 -pip). Anal. calcd for $C_{27}H_{24}N_4$: C, 80.17; H, 5.98; N, 13.85. Found: C, 81.04; H, 6.02; N, 13.94.

1-[4-(2-Methoxyphenyl)piperazinyl]-4-phenylpyrrolo[1,2-a]quinoxaline (1b). Yellow crystals (21%) mp 38 $^{\circ}C$. 1H NMR ($CDCl_3$) δ 9.23 (dd, 1H, J = 7.85 and 2.40 Hz, H-9), 8.01 (dd, 1H, J = 7.85 and 2.40 Hz, H-6), 7.96–7.94 (m, 2H, H-2' and H-6'), 7.56–7.53 (m, 3H, H-3', H-4' and H-5''), 7.52–7.42 (m, 2H, H-7 and H-8), 7.13–7.06 (m, 2H, H-4'' and H-5''), 7.05–7.01 (m, 1H, H-6''), 6.96 (dd, 1H, J = 8.50 and 2.15 Hz, H-3''), 6.92 (d, 1H, J = 4.30 Hz, H-2), 6.61 (d, 1H, J = 4.30 Hz, H-3), 3.93 (s, 3H, CH_3O), 3.65–3.61 (m, 2H, CH_2 -pip), 3.49–3.43 (m, 2H, CH_2 -pip), 3.31–3.12 (m, 4H, CH_2 -pip). ^{13}C NMR ($CDCl_3$) δ 156.2 (C-4), 153.7 (C-2''), 145.2 (C-1''), 142.4 (C-3a), 139.7 (C-5a), 138.7 (C-1''), 131.0 (C-7), 130.8 (C-8), 130.2 (C-9a), 130.1 (C-3' and C-5''), 129.9 (C-2' and C-6'), 127.5 (C-9), 126.3 (C-6), 124.8 (C-5''), 123.5 (C-1), 122.4 (C-4''), 119.7 (C-6''), 117.9 (C-3''), 112.7 (C-3''), 109.5 (C-2), 104.7 (C-3), 56.8 (CH_3O), 54.0 (CH_2 -pip), 52.0 (CH_2 -pip). Anal. calcd for $C_{28}H_{26}N_4O$: C, 77.39; H, 6.03; N, 12.89. Found: C, 77.41; H, 5.94; N, 13.04.

1-(4-Benzylpiperazinyl)-4-phenylpyrrolo[1,2-a]quinoxaline (1c). Yellow oil (41%). 1H NMR ($CDCl_3$) δ 9.15 (dd, 1H, J = 8.00 and 1.70 Hz, H-9), 8.00 (dd, 1H, J = 8.00 and 1.70 Hz, H-6), 7.96–7.92 (m, 2H, H-2' and H-6'), 7.54–7.51 (m, 3H, H-3', H-4' and H-5''), 7.48–7.45 (m, 2H, H-7 and H-8), 7.43–7.41 (m, 2H, H-2'' and H-




Fig. 4 Effects of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives **1a-w** and **2a-f** on Nile Red (NR) efflux in *S. cerevisiae* cells overexpressing (A) the CaCdr1p ABC-transporter (AD-CDR1) and (B) the CaMdr1p MFS-transporter (AD-MDR1). Inhibition of rhodamine 6G (R6G) efflux in the presence of curcumin (70 μ M) (CUR) was taken as positive control for CaCdr1p. Inhibition of [3 H] fluconazole ([3 H] Flu) efflux in the presence of verapamil (90 μ M) was taken as a positive control for CaMdr1p. Values are the means \pm standard deviations (error bars) for three independent experiments. Nile Red was used as the transport substrate at 7 μ M, and its efflux was measured by fluorescence. Each inhibitor was used individually at a 10-fold excess over substrate (70 μ M). The first column of each graph shows the Nile Red efflux in absence of any inhibitor.

6''), 7.41–7.28 (m, 3H, H-3'', H-4'' and H-5''), 6.88 (d, 1H, J = 4.30 Hz, H-2), 6.54 (d, 1H, J = 4.30 Hz, H-3), 3.68 (s, 2H, CH_2), 3.33–3.29 (m, 2H, CH_2 -pip), 3.06–2.97 (m, 4H, CH_2 -pip), 2.60–2.55 (m, 2H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 156.2 (C-4), 145.2 (C-3a), 139.8 (C-5a), 139.3 (C-1''), 138.8 (C-1'), 130.9 (C-7), 130.8 (C-8), 130.6 (C-3' and C-5'), 130.2 (C-9a), 130.1 (C-2'' and C-6''), 129.9 (C-3'' and C-5''), 129.8 (C-2' and C-6'), 128.7 (C-9), 127.5 (C-6), 126.2 (C-4'), 123.4 (C-1), 118.0 (C-4''), 109.3 (C-2), 104.4 (C-3), 64.6 (NCH₂), 54.4 (CH_2 -pip), 53.7 (CH_2 -pip). Anal. calcd for $\text{C}_{28}\text{H}_{26}\text{N}_4$: C, 80.35; H, 6.26; N, 13.39. Found: C, 80.09; H, 6.34; N, 13.57.

1-[4-(Diphenylmethyl)piperazinyl]-4-phenylpyrrolo[1,2-a]quinoxaline (1d). Yellow crystals (68%) mp 69 $^{\circ}\text{C}$. ^1H NMR (CDCl_3) δ 9.12 (dd, 1H, J = 7.40 and 2.20 Hz, H-9), 8.00–7.92 (m, 3H, H-6, H-2' and H-6'), 7.55–7.52 (m, 7H, H-3', H-4', H-5', H-2'' and H-6''), 7.45–7.41 (m, 2H, H-7 and H-8), 7.37–7.31 (m, 4H, H-3'' and H-5''), 7.28–7.21 (m, 2H, H-4''), 6.90 (d, 1H, J = 4.30 Hz, H-2), 6.55 (d, 1H, J = 4.30 Hz, H-3), 4.41 (s, 1H, CH), 3.09–3.00 (m, 4H, CH_2 -pip), 2.48–2.41 (m, 2H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 156.1 (C-4), 145.3 (C-3a), 144.0 (2 C-1''), 139.8 (C-5a), 138.7 (C-1'), 130.9 (C-7), 130.7 (C-8), 130.2 (C-9a), 130.1 (2 C-3'', 2 C-5'', C-3' and C-5'), 129.9 (C-2'' and C-6'), 129.2 (C-2' and C-6'), 128.7 (C-9), 127.5 (C-6), 126.2 (C-4'), 123.4 (C-1), 118.0 (2 C-4''), 109.4 (C-2), 104.3 (C-3), 77.9 (NCH), 54.0 (CH_2 -pip), 53.3 (CH_2 -pip). Anal. calcd for

$\text{C}_{34}\text{H}_{30}\text{N}_4$: C, 82.56; H, 6.11; N, 11.33. Found: C, 83.27; H, 5.82; N, 10.91.

1-(4-Phenethylpiperazinyl)-4-phenylpyrrolo[1,2-a]quinoxaline (1e). Yellow oil (56%). ^1H NMR (CDCl_3) δ 9.15 (dd, 1H, J = 7.90 and 2.35 Hz, H-9), 7.99 (dd, 1H, J = 7.90 and 2.35 Hz, H-6), 7.96–7.92 (m, 2H, H-2' and H-6'), 7.56–7.50 (m, 3H, H-3', H-4' and H-5'), 7.48–7.45 (m, 2H, H-7 and H-8), 7.37–7.32 (t, 2H, J = 7.20 Hz, H-2'' and H-6''), 7.33–7.25 (m, 3H, H-3'', H-4'' and H-5''), 6.89 (d, 1H, J = 4.30 Hz, H-2), 6.55 (d, 1H, J = 4.30 Hz, H-3), 3.38–3.34 (m, 2H, CH_2 -pip), 3.14–3.01 (m, 4H, CH_2 -pip), 2.95–2.90 (ddd, 2H, J = 12.20, 8.55 and 7.40 Hz, CH_2), 2.82–2.76 (ddd, 2H, J = 12.20, 8.55 and 7.40 Hz, CH_2), 2.65–2.58 (m, 2H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 156.1 (C-4), 145.2 (C-3a), 141.3 (C-5a), 139.8 (C-1''), 138.8 (C-1'), 131.0 (C-7), 130.9 (C-8), 130.2 (C-3' and C-5'), 130.1 (C-9a), 130.0 (C-2'' and C-6''), 129.9 (C-3'', C-5'', C-2' and C-6'), 127.6 (C-9), 127.5 (C-6), 126.2 (C-4'), 123.5 (C-1), 117.9 (C-4''), 109.4 (C-2), 104.5 (C-3), 61.8 (NCH₂), 54.4 (CH_2 -pip), 53.6 (CH_2 -pip), 35.0 (CH₂). Anal. calcd for $\text{C}_{29}\text{H}_{28}\text{N}_4$: C, 80.52; H, 6.52; N, 12.95. Found: C, 79.96; H, 6.12; N, 12.92.

1-[4-[(2-Trifluoromethyl)phenethyl]piperazinyl]-4-phenylpyrrolo[1,2-a]quinoxaline (1f). Yellow crystals (63%); mp 34 $^{\circ}\text{C}$. ^1H NMR (CDCl_3) δ 9.16 (dd, 1H, J = 8.20 and 2.00 Hz, H-9), 8.01 (dd, 1H, J = 8.20 and 2.00 Hz, H-6), 7.97–7.93 (m, 2H, H-2' and H-6'), 7.68 (d, 1H, J = 7.80 Hz, H-3''), 7.57–7.48 (m, 5H, H-4', H-3', H-5', H-7



Table 2 Effects of compounds **1** and **2** on Nile Red (NR) efflux by CaCdr1p and CaMdr1p in *S. cerevisiae* cells either overexpressing the Cdr1p ABC-transporter (AD-CDR1) or the Mdr1p MFS-transporter (AD-MDR1)

| Compounds | Yeast strains | ^a MIC ₈₀ (μM) | ^b RI |
|-----------|---------------------|-------------------------------------|-----------------|
| 1c | AD1-8u [−] | 99 ± 10 | 1 |
| | CDR1 | 817 ± 87 | 8.25 |
| | MDR1 | 400 ± 55 | 4.04 |
| 1e | AD1-8u [−] | 12 ± 1.3 | 1 |
| | CDR1 | 810 ± 86 | 67.5 |
| | MDR1 | 789 ± 85 | 65.75 |
| 1g | AD1-8u [−] | 50 ± 6 | 1 |
| | CDR1 | 803 ± 83 | 16 |
| | MDR1 | 221 ± 31 | 4.2 |
| 1j | AD1-8u [−] | 3 ± 0.4 | 1 |
| | CDR1 | 100 ± 12 | 33.3 |
| | MDR1 | 25 ± 3 | 8.33 |
| 1k | AD1-8u [−] | 3 ± 0.2 | 1 |
| | CDR1 | 400 ± 49 | 133.3 |
| | MDR1 | 12 ± 1 | 4 |
| 1l | AD1-8u [−] | 6 ± 0.5 | 1 |
| | CDR1 | 803 ± 102 | 133.8 |
| | MDR1 | 12 ± 2 | 2 |
| 1m | AD1-8u [−] | 12 ± 1.6 | 1 |
| | CDR1 | 408 ± 52 | 34 |
| | MDR1 | 53 ± 6.2 | 4.41 |
| 1n | AD1-8u [−] | 25 ± 3.1 | 1 |
| | CDR1 | 400 ± 53 | 16 |
| | MDR1 | 50 ± 6.2 | 2 |
| 1o | AD1-8u [−] | 6 ± 0.71 | 1 |
| | CDR1 | 200 ± 31 | 33.3 |
| | MDR1 | 25 ± 3.4 | 4.1 |
| 1r | AD1-8u [−] | 6 ± 0.5 | 1 |
| | CDR1 | 776 ± 81 | 129.3 |
| | MDR1 | 12 ± 1.7 | 2 |
| 1s | AD1-8u [−] | 28 ± 1.7 | 1 |
| | CDR1 | 387 ± 47 | 13.8 |
| | MDR1 | 59 ± 4.7 | 2.1 |
| 1t | AD1-8u [−] | 94 ± 7.3 | 1 |
| | CDR1 | 821 ± 75 | 8.7 |
| | MDR1 | 102 ± 9.3 | 1.08 |
| 1w | AD1-8u [−] | 104 ± 8.4 | 1 |
| | CDR1 | 901 ± 77 | 8.6 |
| | MDR1 | 187 ± 16 | 1.7 |
| 2a | AD1-8u [−] | 47 ± 2.9 | 1 |
| | CDR1 | 412 ± 27 | 8 |
| | MDR1 | 91 ± 7.9 | 1.9 |
| 2b | AD1-8u [−] | 94 ± 110 | 1 |
| | CDR1 | 811 ± 119 | 8.6 |
| | MDR1 | 104 ± 121 | 1.1 |
| 2c | AD1-8u [−] | 3 ± 0.1 | 1 |
| | CDR1 | 817 ± 77 | 272.3 |
| | MDR1 | 6 ± 0.2 | 2 |
| 2d | AD1-8u [−] | 6 ± 0.2 | 1 |
| | CDR1 | 831 ± 88 | 138.5 |
| | MDR1 | 5 ± 0.2 | 0.83 |
| 2e | AD1-8u [−] | 3 ± 0.1 | 1 |
| | CDR1 | 821 ± 86 | 273.6 |
| | MDR1 | 6 ± 0.2 | 2 |
| 2f | AD1-8u [−] | 6 ± 0.1 | 1 |
| | CDR1 | 804 ± 71 | 134 |
| | MDR1 | 14 ± 1.2 | 2.33 |

^a The MIC₈₀ values of cytotoxicity were determined by measuring the optical density of cultures of each strain in the absence and the

Table 2 (Contd.)

| Compounds | Yeast strains | ^a MIC ₈₀ (μM) | ^b RI |
|-----------|---------------|-------------------------------------|-----------------|
|-----------|---------------|-------------------------------------|-----------------|

presence of a range of concentrations of the different compounds. Yeast growth in the absence of inhibitor was considered as 100%, and the concentration where the growth was decreased to 80% was taken as MIC₈₀. The values are the means ± standard deviations of three independent experiments. ^b The resistance index (RI) was calculated as the ratio between the MIC₈₀ value determined for the strain overexpressing the transporter relatively to that of the control strain (AD1-8u[−]).

and H-8), 7.46–7.41 (m, 2H, H-4" and H-6"), 7.35 (t, 1H, *J* = 7.60 Hz, H-5"), 6.90 (d, 1H, *J* = 4.25 Hz, H-2), 6.55 (d, 1H, *J* = 4.25 Hz, H-3), 3.38–3.34 (m, 2H, CH₂), 3.13–3.00 (m, 6H, CH₂-pip and CH₂), 2.81–2.76 (m, 2H, CH₂-pip), 2.68–2.61 (m, 2H, CH₂-pip). ¹³C NMR (CDCl₃) δ 156.2 (C-4), 145.1 (C-3a), 140.1 (q, *J* = 1.6 Hz, C-1"), 139.8 (C-1'), 138.8 (C-5a), 133.2 (C-5"), 133.1 (C-6"), 133.0 (C-4"), 131.0 (C-7), 130.9 (C-8), 130.3 (q, *J* = 29.5 Hz, C-2"), 130.2 (C-9a), 130.1 (C-3' and C-5'), 129.9 (C-2' and C-6'), 127.5 (C-9), 127.4 (q, *J* = 5.6 Hz, C-3"), 126.2 (C-6), 126.0 (q, *J* = 272.2 Hz, CF₃), 123.4 (C-1), 117.9 (C-4'), 109.3 (C-2), 104.4 (C-3), 61.6 (NCH₂), 54.3 (CH₂-pip), 53.7 (CH₂-pip), 31.7 (CH₂). Anal. calcd for C₃₀H₂₇F₃N₄: C, 71.98; H, 5.44; N, 11.19. Found: C, 72.23; H, 4.98; N, 11.02.

1-[4-(3-Fluorophenethyl)piperazinyl]-4-phenylpyrrolo[1,2-*a*]quinoxaline (1g). Yellow crystals (49%) mp 56 °C. ¹H NMR (CDCl₃) δ 9.15 (dd, 1H, *J* = 7.80 and 2.10 Hz, H-9), 8.01 (dd, 1H, *J* = 7.80 and 2.10 Hz, H-2), 7.96–7.93 (m, 2H, H-2' and H-6'), 7.55–7.52 (m, 2H, H-3' and H-5'), 7.48–7.43 (m, 2H, H-7 and H-8), 7.31–7.21 (m, 2H, H-5" and H-6"), 7.08–6.88 (m, 2H, H-2" and H-4"), 6.90 (d, 1H, *J* = 4.20 Hz, H-2), 6.56 (d, 1H, *J* = 4.20 Hz, H-3), 3.39–3.35 (m, 2H, CH₂-pip), 3.14–3.07 (m, 4H, CH₂-pip), 2.94–2.89 (m, 2H, CH₂), 2.83–2.80 (m, 2H, CH₂), 2.64–2.61 (m, 2H, CH₂-pip). Anal. calcd for C₂₉H₂₇FN₄: C, 77.31; H, 6.04; N, 12.43. Found: C, 77.46; H, 6.15; N, 12.61.

1-[4-(4-Fluorophenethyl)piperazinyl]-4-phenylpyrrolo[1,2-*a*]quinoxaline (1h). Yellow crystals (55%) mp 150 °C. ¹H NMR (CDCl₃) δ 9.15 (dd, 1H, *J* = 7.70 and 2.10 Hz, H-9), 8.00 (dd, 1H, *J* = 7.70 and 2.10 Hz, H-6), 7.96–7.93 (m, 2H, H-2' and H-6'), 7.55–7.51 (m, 2H, H-3' and H-5'), 7.48–7.44 (m, 2H, H-7 and H-8), 7.30–7.21 (m, 3H, H-2", H-6" and H4'), 7.05 (t, 2H, *J* = 5.55 Hz, H-3" and H-5"), 6.90 (d, 1H, *J* = 4.20 Hz, H-2), 6.56 (d, 1H, *J* = 4.20 Hz, H-3), 3.39–3.35 (m, 2H, CH₂-pip), 3.12–3.07 (m, 4H, CH₂-pip), 2.92–2.88 (m, 2H, CH₂), 2.81–2.76 (m, 2H, CH₂), 2.63–2.60 (m, 2H, CH₂-pip). ¹³C NMR (CDCl₃) δ 162.9 (d, *J* = 242.6 Hz, C-4"), 156.2 (C-4), 144.8 (C-3a), 139.7 (C-5a), 138.8 (C-1'), 136.7 (d, *J* = 3.5 Hz, C-1"), 131.5 (d, *J* = 7.8 Hz, C-2" and C-6"), 131.0 (C-7), 130.9 (C-8), 130.1 (C-9a), 130.2 (C-3' and C-5'), 130.0 (C-2' and C-6'), 127.5 (C-9), 126.3 (C-6), 123.5 (C-1), 117.8 (C-4'), 116.7 (d, *J* = 20.9 Hz, C-3" and C-5"), 109.4 (C-2), 104.5 (C-3), 61.7 (NCH₂), 54.3 (CH₂-pip), 53.4 (CH₂-pip), 34.0 (CH₂). Anal. calcd for C₂₉H₂₇FN₄: C, 77.31; H, 6.04; N, 12.43. Found: C, 77.52; H, 6.17; N, 12.38.

1-[4-(3,4-Dichlorophenethyl)piperazinyl]-4-phenylpyrrolo[1,2-*a*]quinoxaline (1i). Yellow oil (47%). ¹H NMR (CDCl₃) δ 9.13 (dd,






Fig. 5 Effect of compounds **1d** and **1f** on the expression of the GFP-tagged Cdr1p and Mdr1p. Panels (A) AD-CDR1 and (B) AD-MDR1 were evaluated in the presence or in the absence of compounds **1d** and **1f**.

1H, *J* = 8.35 and 2.30 Hz, H-9), 8.00 (dd, 1H, *J* = 8.35 and 2.30 Hz, H-6), 7.96–7.93 (m, 2H, H-2' and H-6'), 7.56–7.51 (m, 3H, H-2' and H-6'), 7.56–7.51 (m, 3H, H-3', H-4' and H-5'), 7.49–7.43 (m, 2H, H-7 and H-8), 7.42–7.37 (m, 2H, H-3" and H-6"), 7.10 (dd, 1H, *J* = 8.35 and 2.30 Hz, H-2"), 6.89 (d, 1H, *J* = 4.30 Hz, H-2), 6.54 (d, 1H, *J* = 4.30 Hz, H-3), 3.37–3.33 (m, 2H, CH₂), 3.08–2.98 (m, 2H, CH₂-pip and CH₂), 2.88–2.72 (m, 2H, CH₂-pip), 2.64–2.56 (m, 2H, CH₂-pip). ¹³C NMR (CDCl₃) δ 156.2 (C-4), 144.9 (C-3a), 141.8 (C-5a), 139.8 (C-1"), 138.8 (C-1'), 133.7 (C-3"), 132.1 (C-5"), 131.7 (C-7), 131.5 (C-4"), 131.0 (C-8), 130.9 (C-2"), 130.1 (C-9a), 130.0 (C-3" and C-5"), 129.9 (C-2' and C-6'), 129.6 (C-6"), 127.5 (C-9), 126.2 (C-6), 123.5 (C-1), 117.9 (C-4'), 109.3 (C-2), 104.4 (C-3), 61.2 (NCH₂), 54.4 (CH₂-pip), 53.7 (CH₂-pip), 34.1 (CH₂). Anal. calcd for C₂₃H₂₄N₄: C, 69.46; H, 5.22; N, 11.17. Found: C, 69.41; H, 5.47; N, 10.95.

4-(4-Phenethylpiperazinyl)pyrrolo[1,2-a]quinoxaline (1j). Yellow oil (81%). ¹H NMR (CDCl₃) δ 7.84 (dd, 1H, *J* = 2.70 and 1.30 Hz,

1H-1), 7.76 (dd, 1H, *J* = 7.80 and 1.60 Hz, H-9), 7.72 (dd, 1H, *J* = 7.80 and 1.60 Hz, H-6), 7.37–7.25 (m, 7H, H-7, H-8, H-2', H-3', H-4', H-5' and H-6'), 6.83 (dd, 1H, *J* = 4.00 and 1.30 Hz, H-3), 6.78 (dd, 1H, *J* = 4.00 and 2.70 Hz, H-2), 3.92–3.88 (m, 4H, CH₂-pip), 2.94–2.88 (m, 2H, CH₂), 2.78–2.70 (m, 6H, CH₂ and CH₂-pip). ¹³C NMR (CDCl₃) δ 154.0 (C-4), 141.8 (C-1'), 137.6 (C-5a), 130.2 (C-3" and C-5'), 129.9 (C-2' and C-6'), 128.9 (C-7), 127.6 (C-9), 127.2 (C-3a), 126.6 (C-6), 125.4 (C-4'), 121.6 (C-9a), 115.8 (C-8), 114.7 (C-1), 113.9 (C-2), 108.3 (C-3), 62.0 (NCH₂), 54.7 (CH₂-pip), 49.5 (CH₂-pip), 35.1 (CH₂). Anal. calcd for C₂₃H₂₄N₄: C, 77.49; H, 6.78; N, 15.72. Found: C, 77.61; H, 6.92; N, 15.94.

4-[4-(3,4-Dichlorophenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1k). Yellow oil (75%). ¹H NMR (CDCl₃) δ 7.82 (dd, 1H, *J* = 2.70 and 1.40 Hz, H-1), 7.74 (dd, 1H, *J* = 7.60 and 1.40 Hz, H-9), 7.70 (dd, 1H, *J* = 7.60 and 1.40 Hz, H-6), 7.38–7.25 (m, 4H, H-7, H-8, H-2' and H-5'), 7.09 (dd, 1H, *J* = 8.10 and 1.80 Hz, H-6'), 6.80 (dd, 1H, *J* = 4.00 and 1.30 Hz, H-3), 6.77 (dd, 1H, *J* = 4.00

Table 3 Ability of compounds **1d** and **1f** to sensitize yeast growth to fluconazole cytotoxicity

| Strain | Compound | ^a FIC of fluconazole | ^b FIC of compound | ^c FICI |
|---------------------|-----------|---------------------------------|------------------------------|----------------------|
| AD1-8u ⁺ | 1d | 1 (1.5/1.5) | 1 (781/781) | 2 (1 + 1) |
| | 1f | 1 (1.5/1.5) | 1 (811/811) | 2 (1 + 1) |
| AD1-CDR1 | 1d | 0.3 (81/209) | 1 (791/791) | 1.3 (0.3 + 1) |
| | 1f | 0.1 (40/209) | 1 (791/791) | 1.1 (0.1 + 1) |
| AD1-MDR1 | 1d | 0.15 (10/65) | 0.0076 (6.25/812) | 0.15 (0.15 + 0.0076) |
| | 1f | 0.15 (10/65) | 0.25 (200/799) | 0.4 (0.15 + 0.25) |
| F2 | 1d | 1 (13/13) | 1 (618/618) | 2 (1 + 1) |
| | 1f | 0.5 (7.5/13) | 1 (400/400) | 1.5 (0.5 + 1) |
| F5 | 1d | 0.4 (200/418) | 0.2 (150/720) | 0.6 (0.2 + 0.4) |
| | 1f | 0.35 (150/418) | 0.43 (350/799) | 0.78 (0.35 + 0.43) |

^a Evaluated by the checkerboard method, and expressed as the fractional inhibitory concentration (FIC) values for the fluconazole (=MIC₈₀ of fluconazole in combination/MIC₈₀ of fluconazole alone). ^b Each compound (=MIC₈₀ of compound in combination/MIC₈₀ of compound alone). The values in brackets are expressed in μ M. ^c FIC index (FICI) value ≤ 0.5 indicates synergistic interaction between the compound and the fluconazole.



and 2.70 Hz, H-2), 3.87–3.83 (m, 4H, CH_2 -pip), 2.85–2.80 (m, 2H, CH_2), 2.76–2.64 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.9 (C-4), 142.0 (C-1'), 137.5 (C-5a), 133.5 (C-3'), 132.0 (C-5'), 131.6 (C-2'), 131.4 (C-4'), 129.6 (C-6'), 128.9 (C-7), 127.2 (C-3a), 126.6 (C-9), 125.4 (C-6), 121.5 (C-9a), 115.8 (C-8), 114.7 (C-1), 113.9 (C-2), 108.2 (C-3), 61.2 (NCH₂), 54.5 (CH_2 -pip), 49.3 (CH_2 -pip), 34.0 (CH_2). Anal. calcd for $\text{C}_{23}\text{H}_{22}\text{Cl}_2\text{N}_4$: C, 64.94; H, 5.21; N, 13.17. Found: C, 65.08; H, 5.36; N, 13.35.

4-[4-(2-Trifluoromethylphenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (11). Yellow oil (79%). ^1H NMR (CDCl_3) δ 7.84 (dd, 1H, J = 2.70 and 1.30 Hz, H-1), 7.75 (dd, 1H, J = 7.80 and 1.40 Hz, H-9), 7.71 (dd, 1H, J = 7.80 and 1.40 Hz, H-6), 7.66 (d, 1H, J = 7.60 Hz, H-3'), 7.50 (t, 1H, J = 7.60 Hz, H-5'), 7.42 (d, 1H, J = 7.60 Hz, H-6'), 7.36–7.26 (m, 3H, H-7, H-8 and H-4'), 6.81 (dd, 1H, J = 4.00 and 1.30 Hz, H-3), 6.78 (dd, 1H, J = 4.00 and 2.70 Hz, H-2), 3.91–3.87 (m, 4H, CH_2 -pip), 3.11–3.06 (m, 2H, CH_2), 2.81–2.70 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.9 (C-4), 140.2 (q, J = 1.6 Hz, C-1'), 137.6 (C-5a), 133.2 (q, J = 0.8 Hz, C-5'), 132.1 (C-6'), 130.0 (q, J = 29.4 Hz, C-2'), 128.9 (C-7), 127.6 (C-4'), 127.3 (q, J = 5.6 Hz, C-3'), 127.2 (C-3a), 126.5 (C-9), 126.1 (q, J = 272.1 Hz, CF₃), 125.3 (C-6), 121.6 (C-9a), 115.8 (C-8), 114.7 (C-1), 113.9 (C-2), 108.2 (C-3), 61.6 (NCH₂), 54.5 (CH_2 -pip), 49.4 (CH_2 -pip), 31.4 (CH_2). Anal. calcd for $\text{C}_{24}\text{H}_{23}\text{F}_3\text{N}_4$: C, 67.91; H, 5.46; N, 13.20. Found: C, 68.05; H, 5.22; N, 13.38.

4-[4-(2-Fluorophenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1m). Yellow oil (74%). ^1H NMR (CDCl_3) δ 7.85–7.82 (m, 1H, H-1), 7.76 (dd, 1H, J = 7.80 and 1.40 Hz, H-9), 7.70 (dd, 1H, J = 7.80 and 1.40 Hz, H-6), 7.36–7.04 (m, 6H, H-7, H-8, H-3', H-4', H-5' and H-6'), 6.81–6.77 (m, 2H, H-2 and H-3), 3.97–3.94 (m, 4H, CH_2 -pip), 3.01–2.98 (m, 2H, CH_2), 2.87–2.83 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 162.6 (d, J = 243.3 Hz, C-2'), 153.9 (C-4), 137.6 (C-5a), 132.4 (d, J = 5 Hz, C-6'), 129.3 (d, J = 8 Hz, C-4'), 128.9 (C-7), 128.5 (d, J = 15.8 Hz, C-1'), 127.2 (C-3a), 126.5 (C-9), 125.4 (d, J = 3.2 Hz, C-5'), 125.3 (C-6), 121.6 (C-9a), 116.7 (d, J = 22.1 Hz, C-3'), 115.8 (C-8), 114.7 (C-1), 113.8 (C-2), 108.2 (C-3), 60.2 (NCH₂), 54.5 (CH_2 -pip), 49.4 (CH_2 -pip), 28.2 (CH_2). Anal. calcd for $\text{C}_{23}\text{H}_{23}\text{FN}_4$: C, 73.77; H, 6.19; N, 14.96. Found: C, 73.85; H, 6.26; N, 15.12.

4-[4-(3-Fluorophenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1n). Yellow oil (81%). ^1H NMR (CDCl_3) δ 7.83 (dd, 1H, J = 2.70 and 1.30 Hz, H-1), 7.73 (dd, 1H, J = 8.00 and 1.50 Hz, H-9), 7.70 (dd, 1H, J = 8.00 and 1.50 Hz, H-6), 7.38–7.23 (m, 3H, H-7, H-8 and H-5'), 7.05–6.89 (m, 3H, H-2', H-4' and H-6'), 6.81 (dd, 1H, J = 3.90 and 1.30 Hz, H-3), 6.77 (dd, 1H, J = 3.90 and 2.70 Hz, H-2), 3.91–3.86 (m, 4H, CH_2 -pip), 2.93–2.87 (m, 2H, CH_2), 2.78–2.69 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 164.3 (d, J = 244.1 Hz, C-3'), 153.7 (C-4), 143.5 (d, J = 7.35 Hz, C-1'), 137.3 (C-5a), 131.3 (d, J = 8.25 Hz, C-5'), 128.9 (C-7), 127.2 (C-3a), 126.6 (C-9), 125.8 (d, J = 2.80 Hz, C-6'), 125.6 (C-6), 121.4 (C-9a), 117.0 (d, J = 20.85 Hz, C-2'), 115.9 (C-8), 114.7 (C-1), 114.5 (d, J = 21.5 Hz, C-4'), 113.9 (C-2), 108.1 (C-3), 61.2 (NCH₂), 54.3 (CH_2 -pip), 48.8 (CH_2 -pip), 34.1 (CH_2). Anal. calcd for $\text{C}_{23}\text{H}_{23}\text{FN}_4$: C, 73.77; H, 6.19; N, 14.96. Found: C, 73.71; H, 6.33; N, 15.16.

4-[4-(4-Fluorophenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1o). Yellow oil (85%). ^1H NMR (CDCl_3) δ 7.83 (dd, 1H, J = 2.70 and 1.20 Hz, H-1), 7.75 (dd, 1H, J = 8.00 and 1.50 Hz, H-9), 7.70 (dd, 1H, J = 8.00 and 1.50 Hz, H-6), 7.37–7.26 (m, 2H, H-7 and H-

8), 7.21 (dd, 2H, J = 8.70 and 5.40 Hz, H-2' and H-6'), 7.04–6.97 (m, 2H, H-3' and H-5'), 6.81 (dd, 1H, J = 3.90 and 1.20 Hz, H-3), 6.77 (dd, 1H, J = 3.90 and 2.70 Hz, H-2), 3.91–3.86 (m, 4H, CH_2 -pip), 2.89–2.84 (m, 2H, CH_2), 2.77–2.66 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 162.8 (d, J = 242.6 Hz, C-4'), 153.8 (C-4), 137.4 (C-5a), 137.0 (d, J = 3.2 Hz, C-1'), 131.5 (d, J = 7.7 Hz, C-2' and C-6'), 128.9 (C-7), 127.2 (C-3a), 126.6 (C-9), 125.5 (C-6), 121.5 (C-9a), 116.6 (d, J = 21.2 Hz, C-3' and C-5'), 115.8 (C-8), 114.7 (C-1), 113.9 (C-2), 108.1 (C-3), 61.8 (NCH₂), 54.5 (CH_2 -pip), 49.1 (CH_2 -pip), 33.9 (CH_2). Anal. calcd for $\text{C}_{23}\text{H}_{23}\text{FN}_4$: C, 73.77; H, 6.19; N, 14.96. Found: C, 73.94; H, 6.05; N, 15.09.

4-[4-(3-Chlorophenyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1p). Pale-yellow oil (73%). ^1H NMR (CDCl_3) δ 7.90–7.88 (m, 1H, H-1), 7.82–7.76 (m, 2H, H-9 and H-6), 7.43–7.28 (m, 2H, H-7 and H-8), 7.26 (t, 1H, J = 8.10 Hz, H-5'), 7.00 (dd, 1H, J = 1.50 and 1.50 Hz, H-2'), 6.93–6.83 (m, 4H, H-4', H-6', H-2 and H-3), 4.01–3.97 (m, 4H, CH_2 -pip), 3.47–3.43 (m, 4H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.9 (C-4), 153.6 (C-1'), 137.3 (C-5a), 136.4 (C-3'), 131.5 (C-5'), 128.9 (C-7), 127.2 (C-3a), 126.7 (C-9), 125.7 (C-6), 121.5 (C-9a), 120.8 (C-8), 117.1 (C-4'), 116.0 (C-2'), 115.2 (C-6'), 114.8 (C-1), 114.0 (C-2), 108.2 (C-3), 49.9 (CH_2 -pip), 49.2 (CH_2 -pip), 33.9 (CH_2). Anal. calcd for $\text{C}_{21}\text{H}_{19}\text{ClN}_4$: C, 69.51; H, 5.28; N, 15.44. Found: C, 69.67; H, 5.07; N, 15.30.

4-[4-(6-Chloro-5-trifluoromethylpyridin-2-yl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1q). White crystals (43%); mp 146 °C. ^1H NMR (CDCl_3) δ 7.88–7.86 (m, 1H, H-1), 7.77–7.73 (m, 2H, H-9 and H-6), 7.72 (d, 1H, J = 8.70 Hz, H-4'), 7.39–7.29 (m, 2H, H-7 and H-8), 6.86–6.80 (m, 2H, H-2 and H-3), 6.51 (d, 1H, J = 8.70 Hz, H-3'), 4.00–3.97 (m, 4H, CH_2 -pip), 3.89–3.86 (m, 4H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 160.6 (C-2'), 153.7 (C-4), 149.0 (q, J = 1.6 Hz, C-6'), 139.0 (q, J = 4.5 Hz, C-4'), 137.2 (C-5a), 128.9 (C-7), 127.2 (C-3a), 126.7 (C-9), 125.7 (C-6), 124.7 (q, J = 269.0 Hz, CF₃), 121.3 (C-9a), 116.0 (C-8), 114.7 (C-1), 114.1 (C-2), 113.8 (q, J = 32.2 Hz, C-5'), 108.2 (C-3), 104.5 (C-3'), 48.6 (CH_2 -pip), 45.7 (CH_2 -pip). Anal. calcd for $\text{C}_{21}\text{H}_{17}\text{ClF}_3\text{N}_5$: C, 58.40; H, 3.97; N, 16.22. Found: C, 58.28; H, 4.07; N, 16.12.

7-Methoxy-4-[4-(2-trifluoromethylphenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1r). Yellow oil (79%). ^1H NMR (CDCl_3) δ 7.78–7.74 (m, 1H, H-1), 7.65 (d, 1H, J = 7.80 Hz, H-3'), 7.64 (d, 1H, J = 8.00 Hz, H-9), 7.51 (t, 1H, J = 7.80 Hz, H-5'), 7.43 (d, 1H, J = 7.80 Hz, H-6'), 7.33 (t, 1H, J = 7.80 Hz, H-4'), 7.20 (d, 1H, J = 2.60 Hz, H-6), 6.91 (dd, 1H, J = 8.00 and 2.60 Hz, H-8), 6.80–6.78 (m, 1H, H-3), 6.76–6.74 (m, 1H, H-2), 3.91–3.84 (m, 7H, CH_3O and CH_2 -pip), 3.13–3.07 (m, 2H, CH_2), 2.84–2.74 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 158.7 (C-7), 154.3 (C-4), 140.3 (q, J = 3.2 Hz, C-1'), 138.7 (C-5a), 133.1 (q, J = 0.8 Hz, C-6'), 133.0 (C-5'), 130.0 (q, J = 29.4 Hz, C-2'), 127.6 (C-9), 127.3 (q, J = 5.6 Hz, C-3'), 126.0 (q, J = 272.2 Hz, CF₃), 121.5 (C-3a), 121.1 (C-9a), 115.5 (C-4'), 115.4 (C-8), 113.9 (C-1), 113.5 (C-2), 110.7 (C-3), 107.9 (C-6), 61.6 (NCH₂), 57.0 (CH_3O), 54.5 (CH_2 -pip), 49.4 (CH_2 -pip), 31.4 (CH_2). Anal. calcd for $\text{C}_{25}\text{H}_{25}\text{F}_3\text{N}_4\text{O}$: C, 66.07; H, 5.54; N, 12.33. Found: C, 65.94; H, 5.67; N, 12.20.

8-Methoxy-4-[4-(2-trifluoromethylphenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1s). Yellow oil (64%). ^1H NMR (CDCl_3) δ 7.73–7.71 (m, 1H, H-1), 7.66 (d, 1H, J = 8.70 Hz, H-6), 7.65 (d, 1H, J = 7.60 Hz, H-3'), 7.48 (t, 1H, J = 7.60 Hz, H-5'), 7.40 (d, 1H, J = 7.60 Hz, H-6'), 7.31 (t, 1H, J = 7.60 Hz, H-4'), 7.19 (d, 1H, J =



2.40 Hz, H-9), 6.95 (dd, 1H, J = 8.70 and 2.40 Hz, H-7), 6.79–6.77 (m, 2H, H-2 and H-3), 3.90 (s, 3H, CH_3O), 3.79–3.78 (m, 4H, CH_2 -pip), 3.11–3.06 (m, 2H, CH_2), 2.80–2.69 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 158.2 (C-8), 152.9 (C-4), 140.2 (q, J = 1.65 Hz, C-1'), 133.2 (q, J = 0.9 Hz, C-6'), 133.1 (C-5'), 131.6 (C-5a), 130.1 (q, J = 29.3 Hz, C-2'), 130.0 (C-6), 127.8 (C-3a), 127.6 (C-4'), 127.3 (q, J = 5.6 Hz, C-3'), 126.0 (q, J = 272.1 Hz, CF_3), 121.9 (C-9a), 115.4 (C-7), 114.0 (C-1), 113.6 (C-2), 107.8 (C-3), 99.3 (C-9), 61.7 (NCH₂), 57.1 (CH_3O), 54.5 (CH_2 -pip), 49.7 (CH_2 -pip), 31.4 (CH_2). Anal. calcd for $\text{C}_{25}\text{H}_{25}\text{F}_3\text{N}_4\text{O}$: C, 66.07; H, 5.54; N, 12.33. Found: C, 66.20; H, 5.44; N, 12.46.

Ethyl 4-[4-(2-trifluoromethylphenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline-2-carboxylate (1t). Pale-yellow crystals (66%); mp 118 °C. ^1H NMR (CDCl_3) δ 8.33 (s, 1H, H-1), 7.75 (d, 1H, J = 8.00 Hz, H-9), 7.67 (d, 1H, J = 8.00 Hz, H-6), 7.64 (d, 1H, J = 7.50 Hz, H-3'), 7.49 (t, 1H, J = 7.50 Hz, H-5'), 7.43 (d, 1H, J = 7.50 Hz, H-6'), 7.41–7.26 (m, 3H, H-7, H-8 and H-4'), 7.19 (s, 1H, H-3), 4.39 (q, 2H, J = 7.20 Hz, OCH_2), 3.89–3.87 (m, 4H, CH_2 -pip), 3.10–3.05 (m, 2H, CH_2), 2.79–2.69 (m, 6H, CH_2 and CH_2 -pip), 1.42 (t, 2H, J = 7.20 Hz, CH_3). ^{13}C NMR (CDCl_3) δ 165.7 (CO), 153.6 (C-4), 140.2 (C-1'), 137.9 (C-5a), 133.1 (C-5'), 133.0 (C-7), 130.0 (q, J = 30.0 Hz, C-2'), 129.0 (C-9), 127.7 (C-6), 127.6 (C-6'), 127.3 (q, J = 5.6 Hz, C-3'), 126.3 (C-3a), 126.0 (q, J = 272.2 Hz, CF_3), 125.6 (C-4'), 121.9 (C-9a), 120.5 (C-2), 119.0 (C-8), 114.9 (C-1), 109.2 (C-3), 61.9 (OCH_2), 61.6 (NCH₂), 54.4 (CH_2 -pip), 49.2 (CH_2 -pip), 31.4 (CH_2), 15.9 (CH_3). Anal. calcd for $\text{C}_{27}\text{H}_{27}\text{F}_3\text{N}_4\text{O}_2$: C, 65.31; H, 5.48; N, 11.28. Found: C, 65.39; H, 5.29; N, 11.42.

2-Phenyl-4-[4-(2-trifluoromethylphenethyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1u). Pale-yellow crystals (67%); mp 136 °C. ^1H NMR (CDCl_3) δ 8.08 (s, 1H, H-1), 7.77 (d, 1H, J = 8.10 Hz, H-9), 7.74–7.68 (m, 3H, H-6, H-2" and H-6"), 7.66 (d, 1H, J = 7.50 Hz, H-3'), 7.51 (t, 1H, J = 7.50 Hz, H-5'), 7.49–7.28 (m, 7H, H-4', H-6', H-7, H-8, H-3", H-4" and H-5"), 7.06 (s, 1H, H-3), 3.93–3.90 (m, 4H, CH_2 -pip), 3.13–3.07 (m, 2H, CH_2), 2.84–2.72 (m, 6H, CH_2 and CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.4 (C-4), 140.2 (C-1"), 137.3 (C-5a), 135.7 (C-1'), 133.4 (C-5"), 133.3 (C-7), 130.3 (C-3' and C-5'), 129.9 (q, J = 29.3 Hz, C-2"), 129.1 (C-9), 128.4 (C-4'), 128.0 (C-6), 127.6 (C-3a), 127.5 (C-2' and C-6'), 127.4 (C-6"), 127.0 (C-2), 126.7 (C-3"), 125.9 (C-8), 125.7 (q, J = 272.2 Hz, CF_3), 125.6 (C-4"), 122.2 (C-9a), 114.7 (C-2), 112.6 (C-1), 105.7 (C-3), 61.2 (NCH₂), 53.9 (CH_2 -pip), 48.7 (CH_2 -pip), 30.7 (CH_2). Anal. calcd for $\text{C}_{30}\text{H}_{27}\text{F}_3\text{N}_4$: C, 71.98; H, 5.44; N, 11.19. Found: C, 72.06; H, 5.53; N, 11.35.

2-Phenyl-4-[4-(3-trifluoromethylbenzyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1v). Yellow oil (54%). ^1H NMR (CDCl_3) δ 8.07 (s, 1H, H-1), 7.76 (d, 1H, J = 7.80 Hz, H-9), 7.73–7.69 (m, 4H, H-6, H-4', H-2" and H-6"), 7.63–7.56 (m, 2H, H-7 and H-8), 7.51–7.43 (m, 3H, H-2', H-3", H-5"), 7.37–7.28 (m, 3H, H-5', H-6' and H-4"), 7.04 (s, 1H, H-3), 3.89–3.86 (m, 4H, CH_2 -pip), 3.67 (s, 2H, NCH₂), 2.71–2.69 (m, 4H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.8 (C-4), 140.3 (C-1"), 137.4 (C-5a), 135.8 (C-1'), 133.9 (C-6"), 132.0 (q, J = 32.0 Hz, C-3"), 130.3 (C-3' and C-5'), 130.2 (C-7), 129.8 (C-3a), 128.9 (C-9), 128.3 (C-4'), 127.4 (C-2' and C-6'), 127.2 (C-5"), 127.1 (q, J = 3.75 Hz, C-2"), 126.9 (C-2), 126.7 (C-6), 125.6 (C-8), 125.5 (q, J = 3.9 Hz, C-4"), 125.4 (q, J = 271.3 Hz, CF_3), 122.3 (C-9a), 114.6 (C-2), 112.4 (C-1), 105.8 (C-3), 63.8 (NCH₂), 54.4 (CH_2 -

pip), 49.3 (CH_2 -pip). Anal. calcd for $\text{C}_{29}\text{H}_{25}\text{F}_3\text{N}_4$: C, 71.59; H, 5.18; N, 11.52. Found: C, 71.75; H, 5.08; N, 11.57.

2-Phenyl-4-[4-(4-trifluoromethylbenzyl)piperazinyl]pyrrolo[1,2-a]quinoxaline (1w). Yellow oil (76%). ^1H NMR (CDCl_3) δ 8.08 (d, 1H, J = 0.90 Hz, H-1), 7.79 (dd, 1H, J = 7.80 and 1.80 Hz, H-9), 7.71–7.67 (m, 3H, H-6, H-2" and H-6"), 7.64–7.55 (m, 2H, H-7 and H-8), 7.48–7.42 (m, 2H, H-3" and H-5"), 7.35–7.29 (m, 3H, H-2', H-6' and H-4"), 7.02 (d, 1H, J = 0.90 Hz, H-3), 3.88–3.85 (m, 4H, CH_2 -pip), 3.68 (s, 2H, NCH₂), 2.72–2.69 (m, 4H, CH_2 -pip). ^{13}C NMR (CDCl_3) δ 153.8 (C-4), 143.8 (q, J = 1.0 Hz, C-1"), 137.5 (C-5a), 135.8 (C-1'), 130.7 (q, J = 28.3 Hz, C-4"), 130.6 (C-7), 130.3 (C-3' and C-5'), 129.7 (C-3a), 129.0 (C-9), 128.3 (C-4'), 127.4 (C-2' and C-6'), 126.7 (C-6), 126.6 (q, J = 6.3 Hz, C-3" and C-5"), 126.5 (q, J = 3.5 Hz, C-2" and C-6"), 125.6 (q, J = 267.8 Hz, CF_3), 125.5 (C-8), 122.4 (C-9a), 114.6 (C-2), 112.4 (C-1), 105.7 (C-3), 63.9 (NCH₂), 54.5 (CH_2 -pip), 49.4 (CH_2 -pip). Anal. calcd for $\text{C}_{29}\text{H}_{25}\text{F}_3\text{N}_4$: C, 71.59; H, 5.18; N, 11.52. Found: C, 71.72; H, 5.04; N, 11.48.

X-ray crystallography studies

Crystallographic data of compounds **1a** and **1h** were collected at 293 K with an Enraf-Nonius CAD-4 diffractometer with monochromatic Cu-K α radiation (λ = 1.54178 Å). The collected data were reduced using the NONIUS CAD4 software and all reflections were used for unit-cell refinement. Then the data were corrected for Lorentz and polarization effects and for empirical absorption correction.⁵¹ The structure was solved by direct methods Shelx 2013 (ref. 52) and refined using Shelx 2013⁵² suite of programs.

Colorless single crystal of **1a** was obtained by slow evaporation from dichloromethane/methanol solution (70/30; v/v): triclinic, space group $P\bar{1}$, a = 9.5233(14) Å, b = 10.8011(19) Å, c = 11.8823(16) Å, α = 107.688(11)°, β = 110.089(10)°, γ = 100.552(11)°, V = 1035.6(3) Å³, Z = 2, δ (calcd) = 1.259 Mg m⁻³, FW = 392.49 for $\text{C}_{26}\text{H}_{24}\text{N}_4$, $F(000)$ = 416. Colorless single crystal of **1h** was obtained by slow evaporation from methanol/dichloromethane (20/80; v/v): triclinic, space group $P\bar{1}$, a = 9.471(10) Å, b = 13.021(6) Å, c = 19.887(6) Å, α = 77.83(4)°, β = 81.76(8)°, γ = 87.25(6)°, V = 2372(3) Å³, Z = 2, δ (calcd) = 1.266 Mg m⁻³, FW = 904.29 for $2\text{C}_{29}\text{H}_{27}\text{FN}_4$, 0.1H₂O, $F(000)$ = 955.

Full crystallographic results have been deposited at the Cambridge Crystallographic Data Centre (CCDC-891809, CCDC-891808, respectively), UK, as ESI.^{†53}

Biological studies

Yeast strains and growth media. All the yeast strains were grown in yeast extract peptone-dextrose (YEPD) broth (HiMedia) and for agar plates, 2.5% (w/v) Bacto agar (Difco, BD Biosciences) was added to the medium. The *S. cerevisiae* strain used as a heterologous host for the expression of Cdr1 and Mdr1 proteins was AD1-8u⁻, provided by Richard D. Cannon, University of Otago, Dunedin, New Zealand. The host AD1-8u⁻ having seven major ABC transporters deleted was suitably modified to clone GFP-tagged Cdr1protein and its mutant variants.⁵⁴ The yeast strains AD1-8u⁻, AD-CDR1, AD-MDR1 (ref. 55–57) were cultured at 30 °C. No trailing effect of the

compound or fluconazole was observed and the false negatives were ruled out as we compare our experimental data with negative control that is AD1-8u⁻ strain (empty vector strain). 15% glycerol stocks of these strains were maintained in -80 °C storage that were freshly revived on YEPD before use.

Reagents and media. Nile Red (>98%), curcumin (purity \geq 99.5%), and verapamil (purity \geq 99%) were obtained from Sigma Chemical Co. Fluconazole (>98%) was obtained from Ranbaxy and [³H]-fluconazole (20 Ci mmol⁻¹) was provided by Moravek Biochemicals and Radiochemicals. All routine chemicals were obtained from HiMedia and were of analytical grade.

Statistical analysis. Data are the means \pm SD from duplicate samples of at least three independent experiments. Differences between the mean values were analyzed by Student's *t* test (GraphPad QuickCalcs: *t*, test calculator), and the results were considered as significant when $p < 0.05$.

Transport assays. Transport assays were implemented by following the accumulation of Nile Red by flow cytometry with a FACsort flow cytometer (Becton-Dickinson Immunocytometry Systems) in cells overexpressing MDR transporters CaCdr1p (AD-CDR1) or CaMdr1p (AD-MDR1). Briefly, the cells with an OD₆₀₀ of 0.1 were inoculated, which were allowed to grow at 30 °C with shaking, until the OD₆₀₀ reached 0.25. The cells were then harvested and resuspended as a 5% cell suspension in diluted medium (containing one part of YEPD and two parts of water). Nile Red was added to a final concentration of 7 μ M, and the cells were incubated at 30 °C for 30 min in absence or presence of each inhibitor at a concentration 10-fold higher than substrate (70 μ M). The cells were then harvested and 10 000 cells were analyzed in the acquisition. The analysis was performed using the CellQuest software (Becton Dickinson Immunocytometry Systems). Efflux of 100% was attributed to the cells not exposed to Nile Red and normalized with the efflux mediated *via* MDR transporters.

Confocal microscopy. Confocal imaging of GFP-tagged Cdr1p and Mdr1p was performed with a Bio-Rad confocal microscope (MRC 1024) with a 100 \times oil immersion. The cells were washed and resuspended in an appropriate volume of 50 mM HEPES (pH 7.0). The cells were placed on the glass slides, and a drop of antifade reagent (Fluoroguard high-performance antifade reagent, Bio-Rad, Hercules, CA, USA) was added to prevent photobleaching.⁵⁵

Cytotoxicity and fractional inhibitory concentration index (FICI) determination. Yeast cells (10^4) were seeded into 96-well plates in either absence or presence of varying concentrations of inhibitors (3–800 μ M), and grown for 48 h at 30 °C. The optical density of each strain at 600 nm was measured for the cell growth. The growth in the absence of any inhibitor was considered as 100%, and the concentration producing 80% of cell growth inhibition was taken as the MIC₈₀ value; the resistance index (RI) was calculated as the ratio between the MIC₈₀ values determined for the strain overexpressing either CaCdr1p (AD-CDR1) or CaMdr1p (AD-MDR1) relative to that of the control strain (AD1-8u⁻). The interaction of the respective inhibitors with fluconazole was evaluated by the checkerboard method⁴³ and was expressed as FICI. The ranges of concentrations used were 1.25–65 μ M for fluconazole, and 3–800 μ M for

the inhibitors. FICI values were calculated as the sum of the FICs of each agent (fluconazole and inhibitors). The FIC of each agent was calculated as the MIC₈₀ of the agent in combination divided by the MIC₈₀ of the agent alone.

Conflicts of interest

There are no conflicts to declare.

References

- 1 M. D. J. Richardson, Changing patterns and trends in systemic fungal infections, *J. Antimicrob. Chemother.*, 2005, **56**, i5–i11.
- 2 M. A. Pfaller, L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar and D. J. Diekema, In vitro susceptibility of invasive isolates of *Candida* spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance, *J. Clin. Microbiol.*, 2007, **46**, 150–156.
- 3 D. S. Perlin, Current perspectives on echinocandin class drugs, *Future Microbiol.*, 2011, **6**, 441–457.
- 4 T. C. White, K. A. Marr and R. A. Bowden, Clinical, cellular, and molecular factors that contribute to antifungal drug resistance, *Clin. Microbiol. Rev.*, 1998, **11**, 382–402.
- 5 R. Prasad, P. De Worgifosse, A. Goffeau and E. Balzi, Molecular cloning and characterisation of a novel gene of *C. albicans*, CDR1, conferring multiple resistance to drugs and antifungals, *Curr. Genet.*, 1995, **27**, 320–329.
- 6 D. Sanglard, F. Ischer, M. Monod and J. Bille, Cloning of *Candida albicans* genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene, *Microbiology*, 1997, **143**, 405–416.
- 7 R. Pasrija, D. Banerjee and R. Prasad, Structure and function analysis of CaMdr1p, a major facilitator superfamily antifungal efflux transporter protein of *Candida albicans*: identification of amino acid residues critical for drug/H⁺ transport, *Eukaryot. Cell*, 2007, **6**, 443–453.
- 8 R. Prasad, S. L. Panwar and Smriti, Drug resistance in yeasts—an emerging scenario, *Adv. Microb. Physiol.*, 2002, **46**, 155–201.
- 9 S. Nim, P. Baghel, V. K. Tran-Nguyen, B. Peres, K. A. Nguyen, A. Di Pietro, P. Falson, R. Prasad and A. Boumendjel, Make azoles active again: chalcones as potent reversal agents of transporters-mediated resistance in *Candida albicans*, *Future Med. Chem.*, 2018, **10**, 2177–2186.
- 10 S. Nim, M. K. Rawal and R. Prasad, FK520 interacts with the discrete intrahelical amino acids of multidrug transporter Cdr1 protein and acts as antagonist to selectively chemosensitize azole-resistant clinical isolates of *Candida albicans*, *FEMS Yeast Res.*, 2014, **14**, 624–632.
- 11 M. Sharma and R. Prasad, The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in *Candida albicans*, *Antimicrob. Agents Chemother.*, 2011, **55**, 4834–4843.



12 M. Sharma, R. Manoharlal, S. Shukla, N. Puri, T. Prasad, S. V. Ambudkar and R. Prasad, Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals, *Antimicrob. Agents Chemother.*, 2009, **53**, 3256–3265.

13 S. Shukla, Z. E. Sauna, R. Prasad and S. V. Ambudkar, Disulfiram is a potent modulator of multidrug transporter Cdr1p of *Candida albicans*, *Biochem. Biophys. Res. Commun.*, 2004, **322**, 520–525.

14 S. Nim, M. K. Rawal and R. Prasad, FK520 interacts with the discrete intrahelical amino acids of multidrug transporter Cdr1 protein and acts as antagonist to selectively chemosensitize azole-resistant clinical isolates of *Candida albicans*, *FEMS Yeast Res.*, 2014, **14**, 624–632.

15 I. Ivnitski-Steele, A. R. Holmes, E. Lamping, B. C. Monk, R. D. Cannon and L. A. Sklar, Identification of nile red as a fluorescent substrate of the *Candida albicans* ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p, *Anal. Biochem.*, 2009, **394**, 87–91.

16 L. R. Basso Jr, C. E. Gast, Y. Mao and B. Wong, Fluconazole transport into *Candida albicans* secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p, *Eukaryot. Cell*, 2010, **9**, 960–970.

17 M. V. Keniya, E. Fleischer, A. Klinger, R. D. Cannon and B. C. Monk, Inhibitors of the *Candida albicans* major facilitator superfamily transporter Mdr1p responsible for fluconazole resistance, *PLoS One*, 2015, **10**, e0126350.

18 G. Campiani, S. Butini, C. Fattorusso, F. Trotta, S. Franceschini, M. De Angelis and K. S. Nielsen, Novel aryl piperazine derivatives with medical utility, PCT Pat., WO2006072608A2, 2006.

19 G. Campiani, F. Aiello, M. Fabbrini, E. Morelli, A. Ramunno, S. Armaroli, V. Nacci, A. Garofalo, G. Greco, E. Novellino, G. Maga, S. Spadari, A. Bergamini, L. Ventura, B. Bongiovanni, M. Capozzi, F. Bolacchi, S. Marini, M. Coletta, G. Guiso and S. Caccia, Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent, *J. Med. Chem.*, 2001, **44**, 305–315.

20 S. Schann, S. Mayer and S. Gardan, Pyrrolo[1,2-*a*]quinoxaline derivatives as adenosine A3 receptor modulators and uses thereof, EP Pat., 20071798233A1, 2007.

21 J. Guillon, P. Grellier, M. Labaied, P. Sonnet, J. M. Léger, R. Déprez-Poulain, I. Forfar-Bares, P. Dallemagne, N. Lemaître, F. Péhourcq, J. Rochette, C. Sergheraert and C. Jarry, Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-*a*]quinoxalines, bispyrrolo[1,2-*a*]quinoxalines, bispyrido[3,2-*e*]pyrrolo[1,2-*a*]pyrazines, and bispyrrolo[1,2-*a*]thieno[3,2-*e*]pyrazines, *J. Med. Chem.*, 2004, **47**, 1997–2009.

22 J. Guillon, I. Forfar, M. Mamani-Matsuda, V. Desplat, M. Saliège, D. Thiolat, S. Massip, A. Tabourier, J. M. Léger, B. Dufaure, G. Haumont, C. Jarry and D. Mossalayi, Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-*a*]quinoxalines as antileishmanial agents, *Bioorg. Med. Chem.*, 2007, **15**, 194–210.

23 J. Guillon, I. Forfar, V. Desplat, S. Belisle-Fabre, D. Thiolat, S. Massip, H. Carrie, D. Mossalayi and C. Jarry, Synthesis of new 4-(*E*)-alkenylpyrrolo[1,2-*a*]quinoxalines as antileishmanial agents by Suzuki-Miyaura cross-coupling reactions, *J. Enzyme Inhib. Med. Chem.*, 2007, **22**, 541–549.

24 J. Guillon, S. Moreau, E. Mouray, V. Sinou, I. Forfar, S. Belisle-Fabre, V. Desplat, P. Millet, D. Parzy, C. Jarry and P. Grellier, New ferrocenic pyrrolo[1,2-*a*]quinoxaline derivatives: synthesis, and *in vitro* antimalarial activity, *Bioorg. Med. Chem.*, 2008, **16**, 9133–9144.

25 J. Guillon, A. Cohen, N. M. Gueddouda, R. Nath Das, S. Moreau, L. Ronga, S. Savrimoutou, L. Basmacyian, A. Monnier, M. Monget, S. Rubio, T. Garerin, N. Azas, J. L. Mergny, C. Mullié and P. Sonnet, Design, synthesis and antimalarial activity of novel bis{N-[pyrrolo[1,2-*a*]quinoxalin-4-yl]benzyl}-3-aminopropyl}amine derivatives, *J. Enzyme Inhib. Med. Chem.*, 2017, **32**, 547.

26 J. Milne, K. D. Normington and M. Milburn, Tetrahydroquinoxalinone sirtuin modulators, PCT Pat., WO2006094210A2, 2006.

27 F. Grande, F. Aiello, O. De Grazia, A. Brizzi, A. Garofalo and N. Meamati, Synthesis and antitumor activities of a series of novel quinoxalinhydrazides, *Bioorg. Med. Chem.*, 2007, **15**, 288–294.

28 V. Desplat, A. Geneste, M. A. Begorre, S. Belisle Fabre, S. Brajot, S. Massip, D. Thiolat, D. Mossalayi, C. Jarry and J. Guillon, Synthesis of new pyrrolo[1,2-*a*]quinoxaline derivatives as potential inhibitors of Akt kinase, *J. Enzyme Inhib. Med. Chem.*, 2008, **23**, 648–658.

29 V. Desplat, S. Moreau, A. Gay, S. B. Fabre, D. Thiolat, S. Massip, G. Macky, F. Godde, D. Mossalayi, C. Jarry and J. Guillon, Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-*a*]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II, *J. Enzyme Inhib. Med. Chem.*, 2010, **25**, 204–215.

30 V. Desplat, M. Vincenzi, R. Lucas, S. Moreau, S. Savrimoutou, N. Pinaud, J. Lesbordes, E. Peyrilles, M. Marchivie, S. Routier, P. Sonnet, F. Rossi, L. Ronga and J. Guillon, Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substituted piperidin-1-yl)]benzyl-phenylpyrrolo[1,2-*a*]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines, *Eur. J. Med. Chem.*, 2016, **113**, 214–227.

31 J. Guillon, M. Le Borgne, C. Rimbault, S. Moreau, S. Savrimoutou, N. Pinaud, S. Baratin, M. Marchivie, S. Roche, A. Bollache, A. Pecci, L. Alvarez, V. Desplat and J. Jose, *Eur. J. Med. Chem.*, 2013, **65**, 205–222.

32 C. Vidaillac, J. Guillon, C. Arpin, I. Forfar-Bares, J. Grellet, S. Moreau, D. H. Caignard, C. Jarry and C. Quentin-Noury, Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of *Staphylococcus aureus*, *Antimicrob. Agents Chemother.*, 2007, **51**, 831–838.



33 C. Vidaillac, J. Guillon, S. Moreau, C. Arpin, A. Lagardère, S. Larrouture, P. Dallemande, D. H. Caignard, C. Quentin-Noury and C. Jarry, Synthesis of new 4-[2-(alkylamino)ethylthio]pyrrolo[1,2-*a*]quinoxaline and 5-[2-(alkylamino)ethylthio]pyrrolo[1,2-*a*]thieno[3,2-*e*]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors, *J. Enzyme Inhib. Med. Chem.*, 2007, **22**, 620–631.

34 S. Wang, A. Folkes, I. Chuckowree, X. Cockcroft, S. Sohal, W. Miller, J. Milton, S. P. Wren, N. Vicker, P. Depledge, J. Scott, L. Smith, H. Jones, P. Mistry, R. Faint, D. Thompson and S. Cocks, Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance, *J. Med. Chem.*, 2004, **47**, 1329–1338.

35 S. Wang, N. C. Wan, J. Harrison, W. Miller, I. Chuckowree, S. Sohal, T. C. Hancox, S. Baker, A. Folkes, F. Wilson, D. Thompson, S. Cocks, H. Farmer, A. Boyce, C. Freathy, J. Broadbridge, J. Scott, P. Depledge, R. Faint, P. Mistry and P. Charlton, Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance, *J. Med. Chem.*, 2004, **47**, 1339–1350.

36 J. Robert and C. Jarry, Multidrug resistance reversal agents, *J. Med. Chem.*, 2003, **46**, 4805–4817.

37 T. Suzuki, N. Fukazawa, K. San-nohe, W. Sato, O. Yano and T. Tsuruo, Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer, *J. Med. Chem.*, 1997, **40**, 2047–2052.

38 P. D. Eckford and F. J. Sharom, ABC efflux pump-based resistance to chemotherapy drugs, *Chem. Rev.*, 2009, **109**, 2989–3011.

39 A. S. Guram, R. A. Rennels and S. L. Buchwald, A simple catalytic method for the conversion of aryl bromides to arylamines, *Angew Chem. Int. Ed. Engl.*, 1995, **34**, 1348–1350.

40 I. Castellote, J. J. Vaquero, J. Fernandez-Gadea and J. Alvarez-Builla, Pyrrolodiazines. 6. Palladium-catalyzed arylation, heteroarylation, and amination of 3,4-dihydropyrrolo[1,2-*a*]pyrazines, *J. Org. Chem.*, 2004, **69**, 8668–8675.

41 I. Castellote, J. J. Vaquero and J. Alvarez-Builla, Palladium-catalysed amination of 2-acyl-1-alkyl-5-bromopyrroles, *Tetrahedron Lett.*, 2004, **45**, 769–772.

42 J. Guillon, S. Moreau, L. Ronga, L. Basmacyan, A. Cohen, S. Rubio, G. Bentzinger, S. Savrimoutou, N. Azas, C. Mullié and P. Sonnet, Design, synthesis and antimalarial activity of some new aminoalcoholpyrrolo[1,2-*a*]quinoxaline derivatives, *Lett. Drug Des. Discov.*, 2016, **13**, 932–942.

43 R. L. White, D. S. Burgess, M. Mandruru and J. A. Bosso, Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test, *Antimicrob. Agents Chemother.*, 1996, **40**, 1914–1918.

44 F. C. Odds, Synergy, antagonism, and what the chequerboard puts between them, *J. Antimicrob. Chemother.*, 2003, **52**, 1.

45 R. Franz, S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke and J. Morschhauser, Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains, *Antimicrob. Agents Chemother.*, 1998, **42**, 3065–3072.

46 R. Franz, M. Ruhnke and J. Morschhauser, Molecular aspects of fluconazole resistance development in *Candida albicans*, *Mycoses*, 1999, **42**, 453–458.

47 M. M. Masood, M. Irfan, P. Khan, M. F. Alajmi, A. Hussain, J. Garrison, Md. T. Rehman and M. Abid, 1,2,3-Triazole-quinazolin-4(3H)-one conjugates: evolution of ergosterol inhibitor as anticandidal agent, *RSC Adv.*, 2018, **8**, 39611–39625.

48 F. Pagniez, N. Lebouvier, Y. M. Na, I. Ourliac-Garnier, C. Picot, M. Le Borgne and P. Le Pape, Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent, *J. Enzyme Inhib. Med. Chem.*, 2020, **35**, 398–403.

49 A. K. Redhu, A. H. Shah and R. Prasad, MFS transporters of *Candida* species and their role in clinical drug resistance, *FEMS Yeast Res.*, 2016, **16**, fow043.

50 V. K. Tran-Nguyen, R. Prasad, P. Falson and A. Boumendjel, Modulators of the efflux pump CaCdr1p of *Candida albicans*: mechanisms of action and chemical features, *Curr. Med. Chem.*, 2017, **24**, 3242–3253.

51 G. M. Sheldrick, *SADABS*, University of Göttingen, Germany, Standard software references, 1996.

52 G. M. Sheldrick, A short history of *SHELX*, *Acta Crystallogr., Sect. A: Found. Crystallogr.*, 2008, **64**, 112–122.

53 Supplementary X-ray crystallographic data.†

54 K. Nakamura, M. Niimi, K. Niimi, A. R. Holmes, J. E. Yates, A. Decottignies, B. C. Monk, A. Goffeau and R. D. Cannon, Functional expression of *Candida albicans* drug efflux pump Cdr1p in a *Saccharomyces cerevisiae* strain deficient in membrane transporters, *Antimicrob. Agents Chemother.*, 2001, **45**, 3366–3374.

55 S. Shukla, P. Saini, Smriti, S. Jha, S. V. Ambudkar and R. Prasad, Functional characterization of *Candida albicans* ABC transporter Cdr1p, *Eukaryot. Cell*, 2003, **2**, 1361–1375.

56 D. Sanglard and F. C. Odds, Resistance of *Candida* species to antifungal agents: molecular mechanisms and clinical consequences, *Lancet Infect. Dis.*, 2002, **2**, 73–85.

57 D. Hiller, D. Sanglard and J. Morschhauser, Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in *Candida albicans*, *Antimicrob. Agents Chemother.*, 2006, **50**, 1365–1371.

